- Home
- AMPX vs TLSI Comparison
AMPX vs TLSI Comparison
Compare AMPX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPX
- TLSI
- Stock Information
- Founded
- AMPX 2008
- TLSI 2010
- Country
- AMPX United States
- TLSI United States
- Employees
- AMPX N/A
- TLSI N/A
- Industry
- AMPX Industrial Machinery/Components
- TLSI Medical Specialities
- Sector
- AMPX Miscellaneous
- TLSI Health Care
- Exchange
- AMPX Nasdaq
- TLSI Nasdaq
- Market Cap
- AMPX 154.4M
- TLSI 124.9M
- IPO Year
- AMPX N/A
- TLSI N/A
- Fundamental
- Price
- AMPX $2.12
- TLSI $3.93
- Analyst Decision
- AMPX Strong Buy
- TLSI Strong Buy
- Analyst Count
- AMPX 7
- TLSI 5
- Target Price
- AMPX $8.17
- TLSI $12.10
- AVG Volume (30 Days)
- AMPX 2.9M
- TLSI 25.0K
- Earning Date
- AMPX 11-07-2024
- TLSI 11-14-2024
- Dividend Yield
- AMPX N/A
- TLSI N/A
- EPS Growth
- AMPX N/A
- TLSI N/A
- EPS
- AMPX N/A
- TLSI N/A
- Revenue
- AMPX $17,480,000.00
- TLSI $26,892,000.00
- Revenue This Year
- AMPX $65.92
- TLSI $61.76
- Revenue Next Year
- AMPX $327.46
- TLSI $47.30
- P/E Ratio
- AMPX N/A
- TLSI N/A
- Revenue Growth
- AMPX 196.22
- TLSI 67.92
- 52 Week Low
- AMPX $0.61
- TLSI $3.32
- 52 Week High
- AMPX $6.02
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- AMPX 63.66
- TLSI 39.39
- Support Level
- AMPX $1.18
- TLSI $3.74
- Resistance Level
- AMPX $2.72
- TLSI $4.66
- Average True Range (ATR)
- AMPX 0.29
- TLSI 0.29
- MACD
- AMPX 0.08
- TLSI 0.02
- Stochastic Oscillator
- AMPX 60.71
- TLSI 20.77
About AMPX Amprius Technologies Inc.
Amprius Technologies Inc is engaged in the production of silicon anodes for high energy density lithium-ion batteries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. All of its revenues is geographically earned in the United States.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.